References
- Labrie F. The major role of androgens in prostate cancer and the need for more efficient blockade. Expert Rev. Endocrinol. Metab.6(3), 313–316 (2011).
- De Souza P, Saad F. Bone health in prostate cancer. Expert Rev. Endocrinol. Metab.6(3), 317–321 (2011).
- Knudsen KE, Kelly WK. Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert Rev. Endocrinol. Metab.6(3), 483–493 (2011).
- Wikström P, Marusic J, Stattin P, Bergh A. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients. Prostate69(8), 799–809 (2009).
- Culig Z. IL-6 causes multiple effects in androgen-sensitive and -insensitive prostate cancer cell lines. Expert Rev. Endocrinol. Metab.6(3), 327–332 (2011).
- Chen M, Carkner R, Buttyan R. The hedgehog/Gli signaling paradigm in prostate cancer. Expert Rev. Endocrinol. Metab.6(3), 453–467 (2011).
- Matuszak EA, Kyprianou N. Androgen regulation of epithelial–mesenchymal transition in prostate tumorigenesis. Expert Rev. Endocrinol. Metab.6(3), 469–482 (2011).
- Nelles JL, Hu W-Y, Prins GS. Estrogen action and prostate cancer. Expert Rev. Endocrinol. Metab.6(3), 437–451 (2011).
- Risbridger GP, Davis ID, Birrell SN, Tilley WD. Breast and prostate cancer: more similar than different. Nat. Rev. Cancer10(3), 205–212 (2010).
- Higa GM. Melding breast and prostate cancers alter egos. Expert Rev. Endocrinol. Metab.6(3), 301–307 (2011).